Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NTLA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 9,000 | $11.99 | $107.9K Sale | Form 4 ↗ |
| Aug 21, 2026 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 2,785 | $13.00 | $36.2K Sale | Form 4 ↗ |
| Aug 20, 2026 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 19,890 | $12.60 | $250.6K Sale | Form 4 ↗ |
| Jul 22, 2026 | Edward J. Dulac III EVP, Chief Financial Officer | NTLA Intellia Therapeutics, Inc. | Sale | 8,111 | $11.25 | $91.2K Sale | Form 4 ↗ |
| Jul 2, 2026 | Edward J. Dulac III EVP, Chief Financial Officer | NTLA Intellia Therapeutics, Inc. | Sale | 4,677 | $18.00 | $84.2K Sale | Form 4 ↗ |
| Jul 1, 2026 | Michael P. Dube VP, Chief Accounting Officer | NTLA Intellia Therapeutics, Inc. | Sale | 2,641 | $16.78 | $44.3K Sale | Form 4 ↗ |
| Mar 2, 2026 | James Basta EVP, General Counsel | NTLA Intellia Therapeutics, Inc. | Sale | 1,211 | $13.78 | $16.7K Sale | Form 4 ↗ |
| Mar 2, 2026 | Eliana Clark EVP, Chief Technical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 607 | $13.78 | $8,364 Sale | Form 4 ↗ |
| Jan 5, 2026 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 34,146 | $9.21 | $314.5K Sale | Form 4 ↗ |
| Jan 5, 2026 | Birgit C. Schultes EVP, Chief Scientific Officer | NTLA Intellia Therapeutics, Inc. | Sale | 8,508 | $9.21 | $78.4K Sale | Form 4 ↗ |
| Jan 5, 2026 | James Basta EVP, General Counsel | NTLA Intellia Therapeutics, Inc. | Sale | 10,397 | $9.21 | $95.8K Sale | Form 4 ↗ |
| Jan 5, 2026 | Fred E. Cohen Director | NTLA Intellia Therapeutics, Inc. | Buy | 150,000 | $9.35 | $1.4M Buy | Form 4 ↗ |
| Jan 5, 2026 | David Lebwohl EVP, Chief Medical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 11,903 | $9.21 | $109.6K Sale | Form 4 ↗ |
| Jan 5, 2026 | Eliana Clark EVP, Chief Technical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 9,515 | $9.21 | $87.6K Sale | Form 4 ↗ |
| Jan 5, 2026 | Edward J. Dulac III EVP, Chief Financial Officer | NTLA Intellia Therapeutics, Inc. | Sale | 6,379 | $9.21 | $58.8K Sale | Form 4 ↗ |
| Jan 5, 2026 | Michael P. Dube VP, Chief Accounting Officer | NTLA Intellia Therapeutics, Inc. | Sale | 2,989 | $9.21 | $27.5K Sale | Form 4 ↗ |
| Dec 11, 2025 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 5,355 | $9.59 | $51.4K Sale | Form 4 ↗ |
| Dec 11, 2025 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 32,832 | $9.47 | $310.9K Sale | Form 4 ↗ |
| Dec 11, 2025 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 49,959 | $9.49 | $474.1K Sale | Form 4 ↗ |
| Oct 1, 2025 | Birgit C. Schultes EVP, Chief Scientific Officer | NTLA Intellia Therapeutics, Inc. | Sale | 31 | $17.38 | $539 Sale | Form 4 ↗ |
| Oct 1, 2025 | Michael P. Dube VP, Chief Accounting Officer | NTLA Intellia Therapeutics, Inc. | Sale | 1,871 | $17.38 | $32.5K Sale | Form 4 ↗ |
| Aug 20, 2025 | William J. Chase Director | NTLA Intellia Therapeutics, Inc. | Buy | 100,000 | $10.03 | $1.0M Buy | Form 4 ↗ |
| Jul 23, 2025 | Edward J. Dulac III EVP, Chief Financial Officer | NTLA Intellia Therapeutics, Inc. | Sale | 7,462 | $14.02 | $104.6K Sale | Form 4 ↗ |
| Jul 2, 2025 | Michael P. Dube VP, Chief Accounting Officer | NTLA Intellia Therapeutics, Inc. | Sale | 2,503 | $9.95 | $24.9K Sale | Form 4 ↗ |
| Jul 1, 2025 | Eliana Clark EVP, Chief Technical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 1,022 | $9.82 | $10.0K Sale | Form 4 ↗ |
| Jul 1, 2025 | Jesse Goodman Director | NTLA Intellia Therapeutics, Inc. | Sale | 1,547 | $9.23 | $14.3K Sale | Form 4 ↗ |
| Jun 30, 2025 | Jesse Goodman Director | NTLA Intellia Therapeutics, Inc. | Sale | 1,547 | $9.56 | $14.8K Sale | Form 4 ↗ |
| Apr 29, 2025 | Muna Bhanji Director | NTLA Intellia Therapeutics, Inc. | Sale | 265 | $8.50 | $2,253 Sale | Form 4 ↗ |
| Mar 4, 2025 | Eliana Clark EVP, Chief Technical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 679 | $8.99 | $6,104 Sale | Form 4 ↗ |
| Mar 4, 2025 | James Basta EVP, General Counsel | NTLA Intellia Therapeutics, Inc. | Sale | 2,572 | $8.99 | $23.1K Sale | Form 4 ↗ |
| Jan 29, 2025 | Muna Bhanji Director | NTLA Intellia Therapeutics, Inc. | Sale | 265 | $9.97 | $2,642 Sale | Form 4 ↗ |
| Jan 3, 2025 | Michael P. Dube VP, Chief Accounting Officer | NTLA Intellia Therapeutics, Inc. | Sale | 1,372 | $12.18 | $16.7K Sale | Form 4 ↗ |
| Jan 3, 2025 | James Basta EVP, General Counsel | NTLA Intellia Therapeutics, Inc. | Sale | 7,074 | $12.18 | $86.2K Sale | Form 4 ↗ |
| Jan 3, 2025 | David Lebwohl EVP, Chief Medical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 9,557 | $12.18 | $116.4K Sale | Form 4 ↗ |
| Jan 3, 2025 | Derek Hicks EVP, Chief Business Officer | NTLA Intellia Therapeutics, Inc. | Sale | 6,502 | $12.18 | $79.2K Sale | Form 4 ↗ |
| Jan 3, 2025 | John M. Leonard President and CEO, Director | NTLA Intellia Therapeutics, Inc. | Sale | 26,807 | $12.18 | $326.5K Sale | Form 4 ↗ |
| Jan 3, 2025 | Laura Sepp-Lorenzino EVP, Chief Scientific Officer | NTLA Intellia Therapeutics, Inc. | Sale | 8,966 | $12.18 | $109.2K Sale | Form 4 ↗ |
| Jan 3, 2025 | Eliana Clark EVP, Chief Technical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 7,422 | $12.18 | $90.4K Sale | Form 4 ↗ |
| Jan 2, 2025 | Eliana Clark EVP, Chief Technical Officer | NTLA Intellia Therapeutics, Inc. | Sale | 556 | $12.03 | $6,689 Sale | Form 4 ↗ |
| Oct 2, 2024 | Michael P. Dube VP, Chief Accounting Officer | NTLA Intellia Therapeutics, Inc. | Sale | 2,012 | $19.01 | $38.2K Sale | Form 4 ↗ |
40 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances